National Reference Centre of Sexually Transmitted Infections Belgium, Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium.
Algemeen Medisch Laboratorium, Antwerp, Belgium.
Euro Surveill. 2024 Feb;29(7). doi: 10.2807/1560-7917.ES.2024.29.7.2300318.
BackgroundAntimicrobial resistance (AMR) of (MG) is a growing concern worldwide and surveillance is needed. In Belgium, samples are sent to the National Reference Centre of Sexually Transmitted Infections (NRC-STI) on a voluntary basis and representative or robust national AMR data are lacking.AimWe aimed to estimate the occurrence of resistant MG in Belgium.MethodsBetween July and November 2022, frozen remnants of MG-positive samples from 21 Belgian laboratories were analysed at the NRC-STI. Macrolide and fluoroquinolone resistance-associated mutations (RAMs) were assessed using Sanger sequencing of the 23SrRNA and gene. Differences in resistance patterns were correlated with surveillance methodology, socio-demographic and behavioural variables via Fisher's exact test and logistic regression analysis.ResultsOf the 244 MG-positive samples received, 232 could be sequenced for macrolide and fluoroquinolone RAMs. Over half of the sequenced samples (55.2%) were resistant to macrolides. All sequenced samples from men who have sex with men (MSM) (24/24) were macrolide-resistant. Fluoroquinolone RAMs were found in 25.9% of the samples and occurrence did not differ between socio-demographic and sexual behaviour characteristics.ConclusionAlthough limited in sample size, our data suggest no additional benefit of testing MG retrieved from MSM for macrolide resistance in Belgium, when making treatment decisions. The lower occurrence of macrolide resistance in other population groups, combined with emergence of fluoroquinolone RAMs support macrolide-resistance testing in these groups. Continued surveillance of resistance in MG in different population groups will be crucial to confirm our findings and to guide national testing and treatment strategies.
全球范围内, (MG)的抗生素耐药性(AMR)日益受到关注,因此需要进行监测。在比利时,样本是自愿送到性传播感染国家参考中心(NRC-STI)的,因此缺乏代表性或稳健的国家 AMR 数据。
我们旨在估计比利时 MG 耐药株的发生率。
2022 年 7 月至 11 月,在 NRC-STI 分析了来自 21 个比利时实验室的 MG 阳性样本的冷冻剩余物。使用 23SrRNA 和 基因的 Sanger 测序评估大环内酯类和氟喹诺酮类耐药相关突变(RAMs)。通过 Fisher 精确检验和逻辑回归分析,将耐药模式的差异与监测方法、社会人口统计学和行为变量相关联。
在收到的 244 份 MG 阳性样本中,有 232 份可用于大环内酯类和氟喹诺酮类 RAMs 的测序。超过一半的测序样本(55.2%)对大环内酯类耐药。所有来自男男性行为者(MSM)的测序样本(24/24)均对大环内酯类耐药。氟喹诺酮类 RAMs 出现在 25.9%的样本中,且在社会人口统计学和性行为特征方面的发生率无差异。
尽管样本量有限,但我们的数据表明,在做出治疗决策时,在比利时,从 MSM 中检测 MG 是否对大环内酯类耐药没有额外的益处。在其他人群中,大环内酯类耐药的发生率较低,同时出现氟喹诺酮类 RAMs,支持在这些人群中进行大环内酯类耐药检测。在不同人群中持续监测 MG 的耐药性对于证实我们的发现并指导国家检测和治疗策略至关重要。